About us
The European industry association for combined products
Who we are
The MPP Association is a European industry association dedicated to enhancing synergies between the pharma, medtech and tech sectors to develop and improve access to health technologies. Our association provides industry actors with the opportunity to exchange knowledge and collaborate in technology and regulatory areas, and to make themselves heard at the European level.
The MPP represents companies combining health technologies such as medicinal product, medical devices or in vitro diagnostics (IVDs) and digital technologies for a medical purpose.
The MPP Association is a recognized stakeholder by the European Medicines Agency (EMA) and engages with regulators, national competent authorities, notified bodies and key stakeholders.
The Medtech & Pharma Platform is a not-for-profit association in accordance with Articles 60 et seq. of the Swiss Civil Code. The MPP Association is registered in the EU Transparency register, ID 234427831877-10.
Objectives
The combined use of health technologies is the future of healthcare, bringing together the best of medicinal products, medical devices and IVDs, and digital health innovation. It supports:
- The competitiveness of the European healthcare industry
- The development of personalized medicine and home-based healthcare
- The improvement of patient outcomes and adherence
- The increased effectiveness of public spending in healthcare
These technologies have a positive impact and hold great promises for research and for many therapeutic areas, improving patient outcomes. Examples include:
- Cancer
- Cardiovascular diseases
- Comorbidities
- Anti-microbial resistance
- Unmet medical needs
- Pandemics
Development
The development of the combined use of health technologies is facing certain challenges, which the MPP Association addresses in coordination with European institutions and other stakeholders. These challenges include the following aspects:
Regulatory challenges
In the absence of specific legislation, combined products are regulated under the different frameworks for medicinal products, medical devices and digital technologies, which lead to uncertainties and gaps
Regulatory challenges
In the absence of specific legislation, combined products are regulated under the different frameworks for medicinal products, medical devices and digital technologies, which lead to uncertainties and gaps
Development challenges
The development of combined products requires new ways of cooperation between the pharma, medtech and tech industries and a clear definition of the respective roles and responsibilities
Development challenges
The development of combined products requires new ways of cooperation between the pharma, medtech and tech industries and a clear definition of the respective roles and responsibilities
Cybersecurity and privacy of personal health data
Cybersecurity and privacy of personal health data
The association draws together companies from the pharma, medtech and tech sectors. It provides opportunities to:
- Foster synergies and new collaboration models between the pharma, medtech and tech industries to accelerate patients’ access to safe and innovative health technologies and reinforce the competitiveness of the European healthcare industry
- Support the development of a balanced and proportionate regulatory and political framework ensuring the safety of the combined used of health technologies and the protection of health data
